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Abstract
Osteoporosis has been associated with pulmonary silicosis in California horses exposed to
soils rich in cytotoxic silica dioxide crystals, a syndrome termed silicate associated osteopo-
rosis (SAO). The causal mechanism for the development of osteoporosis is unknown. Oste-
oporotic lesions are primarily located in bone marrow-rich sites such as ribs, scapula and
pelvis. Gene transcription patterns within bone marrow and pulmonary lymph nodes of
affected horses may offer clues to disease pathobiology. Bone marrow core and tracheo-
bronchial lymph node tissue samples harvested postmortem from affected and unaffected
horses were examined histologically and subjected to RNA sequencing (RNA-seq).
Sequenced data were analyzed for differential gene expression and gene ontology. Meta-
transcriptomic and metagenomic assays evaluated samples for infectious agents. Thirteen
of 17 differentially expressed transcripts in bone marrow were linked to bone and cartilage
formation such as integrin binding bone sialoprotein (log2FC = 3.39, PFDR = 0.013) and
chondroadherin (log2FC = 4.48, PFDR = 0.031). Equus caballus solute carrier family 9, sub-
family A2 (log2FC = 3.77, PFDR = 0.0034) was one of the four differentially expressed tran-
scripts linked to osteoclast activity. Osteoblasts were hyperplastic and hypertrophic in bone
marrow from affected horses. Biological pathways associated with skeletal morphogenesis
were significantly enriched in affected horses. The 30 differentially expressed genes in
affected lymph nodes were associated with inflammatory responses. Evidence of infectious
agents was not found. The SAO affected bone marrow molecular signature demonstrated
increased transcription and heightened activation of osteoblasts. Increased osteoblastic
activity could be part of the pathological mechanism for osteoporosis or a compensatory
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response to the accelerated osteolysis. Transcriptome data offer gene targets for inquiries
into the role of osteocytes and osteoblasts in SAO pathogenesis. Viral or bacterial infectious
etiology in SAO is less likely based on metatranscriptomic and metagenomic data but can-
not be completely ruled out.
Introduction
Progressive osteoporosis is a comorbid condition in horses that have chronic pulmonary sili-
cosis.[1] Clinical manifestations of osteoporosis include debilitating skeletal deformities, cervi-
cal osteoarthritis, and pathological fractures.[1, 2] Lytic bone lesions are typically found in
ribs, vertebrae, scapulae, and the pelvis.[1, 3] Osteoporosis is more strongly associated with sil-
icotic lymphadenitis in the nodes that drain the lung parenchyma (tracheobronchial lymph
nodes (tLNs)), than with pulmonary silicosis.[1] The condition is termed silicate associated
osteoporosis (SAO) when the skeletal and thoracic (lung and tLN) lesions are present simulta-
neously.[1] Cases of SAO are geographically clustered in regions with soil containing high lev-
els of cytotoxic silicates (e.g., cristobalite—SiO2 polymorph), which are aerosolized and
inhaled as fine crystalline silicate particles. [2, 4] Other causes of chronic granulomatous pul-
monary disease have not been found in affected horses.[1] The pathogenic link between silico-
sis and osteoporosis remains putative.
Abnormal bone remodeling and anomalous osteoclast morphology (hypertrophy, hyper-
plasia), coupled with excessive osteolysis in SAO, are histologically similar to the lytic phase of
Paget’s disease of bone (PDB) in people.[5] However, the chronic pulmonary inflammation
induced by cytotoxic silicates, age of onset, skeletal distribution, and progressive osteolysis set
SAO apart from PDB [1, 3, 5] (reviewed by Nebot Valenzuela et al. [6]). The roles of immuno-
logical background and other contributing factors for the development of SAO, such as dose
and duration of exposure to the silicate crystals warrant further investigation. A previous
investigation did not reveal viral or bacterial infections as cofactors in SAO through culture
and microscopic examination of affected tissues, however broad metatranscriptomic and
metagenomic assays to look for novel infectious agents have not been performed.[1] Though
bone lesions have been well characterized grossly and morphologically in SAO, the underlying
cause of the pathologic osteolysis is unknown.
SAO has only been reported in horses. However, singular cases of similar comorbidities
have been suspected to occur in humans. [7–9] Osteoporosis has been associated with pulmo-
nary diseases such as cystic fibrosis [10] and chronic obstructive pulmonary disease in people.
[11, 12] Other extra-skeletal inflammatory diseases associated with osteoporosis include
inflammatory bowel disease [13] and systemic lupus erythematosus. [14] Hyper-activation of
osteoclasts during systemic inflammation suggests that a subset of pro-inflammatory signals
may induce osteoporosis.[15]
Merging of osteoclast activation and pro-inflammatory signals is in part supported by
molecular studies. Osteoclast differentiation and activation are regulated mainly through an
interaction between “receptor activator of nuclear factor κ-β” (RANK) and its ligand
(RANKL).[16] Pro-inflammatory cytokines like IL1, TNFα and IL6 potentiate RANK down-
stream signaling cascades, or increase paracrine production of RANKL. Thus, these pro-
inflammatory cytokines can increase osteoclast activity.[17] Therefore, osteolysis in SAO may
be derived from chronic cytotoxic silicate-induced inflammation within the respiratory tract.
We hypothesized that the inflammatory trigger initiates aberrant osteoclastogenesis in the
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bone marrow (BM), where osteoclast precursors receive systemic signals, resulting in acceler-
ated osteolysis and osteoporosis in affected horses.
To test our hypothesis we generated differential gene expression (DGE) profiles of the main
tissue sites affected by SAO, the rib BM and tLN, in affected and unaffected horses. Because of
the hypothesized systemic effect of pro-osteoclastogenic trigger, BM samples were collected
away from gross lesions of osteoporosis with markedly altered cell populations. This tissue col-
lection protocol was designed to capture the pattern of cellular signals before significant tissue
heterogeneity would dominate the transcriptional differences. The presence of transcripts
from infectious agents in the target tissues was also evaluated.
Material and methods
Animals
Samples from the two tissue targets, BM cores and tLNs, were collected post mortem from sex
and age-matched SAO+ and SAO- horses (S1 Table). There is no known breed predisposition
for SAO.[1] To prevent inclusion of subclinically affected horses in the control group, inclu-
sion criteria for control horses included absence of exposure to SAO endemic regions (i.e.,
exposure to cytotoxic silica dioxide particles) and absence of granulomatous pulmonary dis-
ease on post mortem examination. Study animals consisted of 8 SAO-affected, (3 females:
Appaloosa, Quarter Horse and Thoroughbred, and 5 males: Holsteiner, Quarter Horse cross,
Quarter Horse, Paint and Arabian), and 8 unaffected horses, (4 females: Hanoverian, Thor-
oughbred, Paint and Quarter Horse, and 4 males: Quarter Horse, Standardbred/Arabian cross,
Mustang cross, and Morgan/Arabian cross). The median age of SAO+ horses in BM tissue
group (n = 8, 20 years, range 12 to 30) was not significantly different (Mann-Whitney test,
p = 0.46) from the median age of unaffected horses (n = 8, 17.5 years, range 8 to 26). Similarly,
the median age of SAO+ horses in tLN tissue group (n = 7, 19 years, range 12 to 30) was not
significantly different (Mann-Whitney test, p = 0.48) from the median age of the unaffected
horses (n = 6, 17 years, range 11 to 26). Clinical disease in SAO horses was categorized as mild
or severe based on the absence or presence, respectively, of gross skeletal deformities. Formal
consent was obtained from owners for horses donated to the study. All horses were euthanized
with an intravenous overdose of pentobarbital sodium (FATAL-PLUS—Pentobarb ital Sodium
390 mg/mL, Vortech Pharmaceuticals, Dearborn, MI) solution (>100 mg/kg) due to poor
quality of life (SAO horses) or neurologic, chronic focal musculoskeletal or behavioral abnor-
malities, or trauma (S1 Table). The project was approved by the University of California Davis
Institutional Animal Care and Use Committee.
SAO clinical phenotyping
The medical history included known exposure to SAO endemic regions. Musculoskeletal con-
ditions including history of skeletal deformities, lameness, fracture(s), decreased range of
motion, and exercise intolerance, as well as abnormalities of the respiratory system were inves-
tigated and documented. Ante mortem clinical evaluation included physical examination and
complete blood cell count and serum biochemistry including ionized calcium concentrations.
All horses in the study received non-steroidal anti-inflammatory (NSAIDs) medications (e.g.
flunixin meglumine, firocoxib, or phenylbutazone) at standard dosing regiments for pain
management prior to euthanasia. Horses treated with bisphosphonates, including zoledronic
acid (Zometa), clodronate (Osphos) and tiludronate (Sigma), within the past twelve months
were excluded from the study. The diagnosis of SAO was confirmed by post mortem evidence
of silicosis in the tLN and osteoporosis.[1]
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Post mortem evaluation
The skull, scapulae, humeri, ribs, pelvis, lungs, lymph nodes (cervical, thoracic and abdomi-
nal), endocrine organs (pituitary, thyroid, and adrenal glands; parathyroid glands were exam-
ined in 3 of the affected and 2 control horses due to the difficulty in finding the parathyroid
glands in this specie), skeletal muscles, major abdominal organs and reproductive organs
(when present) were evaluated grossly and histologically. Sections of the 7th, 8th, 9th, or 10th rib
and other bones were evaluated microscopically to confirm SAO status when bone deformity,
porosity, fracture, or discoloration were present.
Histology
All tissues were fixed in 10% buffered formalin. Rib BM cores specimens were decalcified with
10% ethylenediaminetetraacetic acid (EDTA; Amresco, Solon, OH) at 4˚C for 2 weeks prior to
trimming and sectioning. Trimmed tissues underwent routine histological processing result-
ing in 4μm sections stained with hematoxylin and eosin using routine protocols.
Microscopic features used to confirm silicosis in tLNs included necrotizing and fibrosing
granulomas with intralesional refractile crystals. Features used to confirm osteoporosis
included atypically large and numerous intralesional osteoclasts with increased numbers of
nuclei, and abnormal bone tissue remodeling characterized by haphazard, anastomosing, thin,
woven and lamellar bone trabeculae with mosaic cement lines in areas of prior lysis.
Bone formation and resorption ratios were calculated using the length (in μm) of bone sur-
face covered by osteoblasts or scalloped sites of resorption (Howship’s lacunae), respectively,
to the total length of bone surface (bone perimeter) using digital images of histological sections
obtained at 100x magnification (image area = 877x666μm). Image software (Adobe Photoshop
CS6, Adobe Systems Incorporated, San Jose, CA) was used for the analysis of images with suffi-
cient morphological detail for cell and tissue identification (2–6 per specimen). The measuring
scale was set to the calibration bar embedded in the images. Bone formation surface was
defined as bone surface length in μm lined by osteoblasts. Bone resorption surfaces were
defined by length in μm of scalloped bone surface contours. Osteoblast height, as a reflection
of osteoblast hypertrophy and activity, was defined as the average apical to basilar distance
in μm of 3 to 5 osteoblasts per image. Bone surfaces with artifacts and/or indistinct cellular
morphology as well as surfaces created at the image edges were excluded from analysis. The
calculated ratios were compared between SAO+ and unaffected horses using a two-sided t-test
with p<0.05 considered statistically significant.
Tissue targets for transcriptome sequencing and DGE analysis
Rib BM cores and tLN are characteristically affected in SAO and, therefore, were the target
sites for in situ transcription profiling of SAO+ and unaffected horses. Rib BM core samples
were collected away from grossly visible rib lesions.
The interval from euthanasia to the time of BM collection ranged from 20 min to 2 hours.
However, one sample (SAO6) was preserved at 4˚C for 12hrs post mortem and included in the
study after passing RNA quality assessment (defined in the next paragraph). BM was collected
aseptically by removing a segment of cortical bone with handsaw (Bosch PS50-2B, Mt. Pros-
pect, IL) at the middle of the rib (7, 8, 9 or 10). The BM sample included both trabecular bone
and inter-trabecular tissues. Transverse segments of tLN, including the cortex and medulla,
were collected during necropsy, within 1–4 hours after euthanasia. Approximately 5 mm
cubes of BM and tLN samples were placed into individual 1.8 ml cryogenic tubes (Nunc Cryo-
Tubes Sigma-Aldrich, Roskilde, Denmark) filled with 1.5mL of RNA–preserving solution
(RNAlater, Vilnius, Lithuania) and immediately cryopreserved in liquid nitrogen. Samples
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were stored at -80˚C until RNA extraction. Next, a second set of samples of the BM and tLNs
from the same site were fixed in 10% buffered formalin for microscopic examination.
RNA extraction and quality validation
The tissues stored in RNAlater were thawed on ice and sectioned using sterile instruments
into ~0.3 cm cubes. The tissue cubes were individually crushed within liquid nitrogen to a fine
powder using a sterile and UV-light-treated ceramic mortar and pestle also cleaned with
RNase inhibiting solution (RNaseZAP wipes, Sigma-Aldrich, Saint Louis, MO). Total RNA
was extracted using a commercial kit (RNeasy Plus Mini Kit, Qiagen, Hilden, Germany) fol-
lowing manufacturer’s protocol. Any contaminating genomic DNA was degraded enzymati-
cally (RNase-Free DNase I and RNeasy Mini Elute Clean Up kits, Qiagen). An aliquot of the
resulting total RNA with absorbency ratio (A260nm/280nm) of>1.9 was quantified spectrophoto-
metrically (NanoDrop 1000, ThermoFisher Scientific, Waltham, MA) at 260nm wavelength.
The quality of the RNA was assessed using a capillary electrophoresis technique (Agilent 2100
Bioanalyzer, Agilent Technologies, Santa Clara, CA, (S1 Table)).
RNA-seq library construction and RNA sequencing
Samples of total RNA (500ng) with RIN of 7.5 were submitted to the DNA Technologies
Core (University of California Davis Genome Center) and used for construction of strand-
specific, poly-A enriched libraries. Following stranded mRNA-Seq Kit (KAPA Stranded
mRNA-Seq Kit, Illumina platform, Cape Town, South Africa) manufacturer’s protocol, poly-A
enrichment followed by cDNA synthesis and A tailing adapter ligation was performed. Library
amplification was completed in 10 PCR cycles. Capillary electrophoresis technique (Agilent
2100 Bioanalyzer, Agilent Technologies, Santa Clara, CA) assessed distribution of the library
fragments. Libraries were pooled and sequenced across two lanes with specification of 100-bp
paired-end reads (100PE), (Illumina HiSeq 3000, San Diego, CA).
Sequence reads quality assessment, trimming, and alignment
Raw reads were processed with expHTS [18] to trim low quality reads and adapter contamina-
tion, and to remove PCR duplicates. Trimmed reads for each sample were aligned to the Equ-
Cab2 horse genome with EquCab2.83 annotation (Ensembl), using STAR v. 2.5.1a aligner,
[19] which also generated raw read counts per gene that were the input for the statistical
analysis.
Differential gene expression analyses
Differential gene expression analyses were conducted using the statistical limma-voom pi-
peline (version 3.28.17) [20] [21] and ANOVA statistical model that factors in presence of
disease (affected/ unaffected), osteoporosis phenotype (mild, severe), tissue type (BM, tLN),
and RNA isolation batch. Statistical significance of the genes was associated with an adjusted
p value of<0.05. GO enrichment analysis was conducted (Bioconductor package topGO:
Enrichment Analysis for Gene Ontology. R package version 2.24.0) to identify biological func-
tions enriched in SAO+ tissues transcriptome.[22]
PANTHER pathway analysis
The files of genes from the DGE analysis with ENSEMBL gene IDs and fold-change expressed
in log2 for BM and LN tissues were loaded into Gene List Analysis (http://www.pantherdb.org,
https://doi.org/10.1093/nar/gkw1138). The settings included statistical enrichment test
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defaults and Equus Caballus (EquCab2.0) as the reference species. Statistical significance was
set as p-value below the Bonferroni correction was used to accounted for multiple comparisons
in the analysis. PANTHER Pathways and GO-Slim Biological Processes were selected as the
Annotation Data Sets for analysis.
BRAKEN (Bayesian Re-estimation of Abundance after Classification with
KrakEN) analysis
Because the pathogenesis of SAO is unknown, non-equine reads were evaluated for similarity
to sequences of infectious agents that could be attributed to viruses or bacteria. Trimmed reads
were evaluated with KrakEN, a k-mer based metagenomic classification tool, using a combined
horse, viral, and bacterial database, followed by the BRAKEN metagenomic classification pipe-
line for transcription frequency of non-equine genetic material, and reported as fractions rela-
tive to the Equus Caballus taxonomy labels assigned by KrakEN.[23–25]
Metagenomic analysis, viral discovery
Metagenomic analysis evaluated SAO+ tissues for viral transcripts. Samples of SAO+ BM and
tLN SAO1, SAO7, SAO3, SAO9 (not used in transcriptome study)), as well as buffy coat
(SAO7, SAO9) and lung (SAO1, SAO3) tissues were pooled. Viral capsid-protected nucleic
acid was extracted and enriched according to an established protocol.[26] An Illumina MiSeq
library was constructed using random RT-PCR followed by use of the Illumina Nextera kit
and sequenced on an Ilumina MiSeq platform using 250 bases paired end. Sequence reads
were de novo assembled using the Ensemble program and contigs and singletons then trans-
lated into hypothetical protein sequences, which were compared to all viral proteins in the
NCBI virus RefSeq database using BLASTx. Detailed descriptions of the methods used in this
analysis are included as supplemental material (S1 Protocol).
RNA mapping statistics
Sufficient depth of sequencing and an adequate mapping rate were achieved for the DGE
analysis. The average reads across BM and tLN samples were ~25.7 million reads/sample.
Following trimming adapter contamination and removal of low quality reads and PCR
duplicates with expHTS software, the average mapping rate to EquCab2.0 was 92.63%, where
54.6% reads uniquely aligned to an annotated horse gene and 32.4% aligned to regions of
genome without annotation. 5.28% of reads aligned to multiple regions in the genome and
0.35% aligned with some annotation overlap, therefore, these reads were not assigned to a
specific gene.
Samples segregate based on tissue type and disease phenotype
The biologically relevant segregation of the sampled tissues in the MDS plots demonstrated
high quality of starting genetic material, sequencing, and mapping techniques (S1–S3 Figs).
The MDS plots illustrated that the clustering of SAO+ and SAO- transcriptomes in BM and
tLN tissues were most influenced by the tissue origin (S1 Fig), and the disease phenotype (S2
and S3 Figs), rather than biological variations such as breed or age (S5 and S6 Figs) among
horses. SAO+ BM samples with mild osteoporosis phenotype clustered with unaffected sam-
ples (S2 Fig).
Transcriptome profile in equine osteoporotic condition associated with pulmonary silicosis
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Results
Differential gene expression in BM and tLN
The ANOVA statistical model that accounted for the osteoporosis phenotype resulted in 17
significantly differentially expressed genes in BM and 36 significantly differentially expressed
genes in tLN tissue (list of selected genes in Tables 1 and 2 and S2 and S3 Tables).
Bone marrow differential gene expression
Overall 12 of 17 differentially expressed genes (relative to unaffected animals) in SAO+ BM
were found to be associated with skeletal formation (Table 1). Sixteen of the transcripts were
increased in SAO, with decreased expression only found in hydroxysteroid (17-beta) dehydro-
genase 6, (HSD17B6). Among the genes with increased transcripts, Equus caballus solute car-
rier family 9, subfamily A2 (SLC9A2) expression is linked to osteoclast differentiation and
survival.[27] Transient receptor potential cation channel, subfamily V, member 4 is a marker
of osteoclast differentiation (TRPV4).[36] Osteomodulin (OMD) [28] and distal-less homeo-
box 3 (DLX3)[30] gene products are transcriptional indicators of osteoclast activity and differ-
entiation, respectively. Death-associated protein kinase 2 (DAPK2),[41, 52] was the only
Table 1. Seventeen differentially expressed genes in SAO+ BM tissue listed in tissue function groups with base 2 logarithmic fold change and false discovery
adjusted p-value.
Tissue Function Gene Specific Function Log2FC,
(PFDR)
Bone resorption Equus caballus solute carrier family 9,
subfamily A2 (SLC9A2)
Na+/H+ exchanger, cation proton antiporter; expressed in osteoclasts [27] 3.77 (0.034)
Bone resorption,
formation, and
maintenance
Osteomodulin, Osteoadherin (OMD) Bone homeostasis and mineralization couples activity of Oc and Ob [28, 29] 3.92 (0.013)
Distal-less homeobox3 (DLX3) Homeobox gene embryonic bone development, Ob differentiation and Os
function; Oc differentiation [30, 31] Higher expression in Os compared to
Ob [32]
4.49 (0.033)
Transient receptor potential cation
channel, subfamily V, member 4 (TRPV4)
Skeletal development at the growth plate; cartilage homeostasis [33–35] and
osteoclast differentiation [36]
3.77 (0.030)
Bone homeostasis and
formation
Collagen type XXIV, alpha 1 (COL24A1) Precedes collagen I deposition in ossification centers [37] 4.18 (0.013)
Sp7 transcription factor (SP7), Osterix (Osx) Ob and chondrocyte differentiation from mesenchyme [38–40]; functions
downstream of Runx2, BMP, Wnt [41]
3.32 (0.031)
Integrin binding sialoprotein, bone
sialoprotein (BSP)
Mineralization of bone and cartilage during bone development [42] 3.93 (0.013)
Osteocalcin; bone gamma-
carboxyglutamate (gla) protein (BGLAP)
Bone mineralization; regulated by Runx2 and Dlx3 and produced by in BM
pluripotent cells during osteogenesis [31, 43, 44]
2.44 (0.029)
Sphingomyelin phosphodiesterase 3
(SMPD3)
Endochondral bone formation in skeletal development [45, 46] 2.70 (0.021)
Collagen type XI, alpha 2 (COLXIA2) Skeletal development as cartilage ECM, embryonic development of the
skeleton [47]
3.37 (0.029)
Chondroadherin (CHAD) Embryonic development of the skeleton, [48] minor component of bone
matrix, [49] higher expression in Ob than Os [32]
4.48 (0.031)
Anoctamin 5 (ANO5) Embryonic development developing somites; Growth-plate chorndrocytes;
Ob [50]
3.94 (0.037)
Hydroxysteroid (17-beta) dehydrogenase 6
(HSD17B6)
Epimerization / interconversion estrone (E1) and estradiol (E2) [51] -2.99
(0.013)
WAP four-disulfide core domain 1
(WFDC1)
Secreted protease inhibitor with higher expression in Ob than Os [32] 2.67 (0.038)
Cadherin 15 (CDH15) Cell adhesion molecule with higher expression in Os than Ob [32] 3.97 (0.034)
Inflammation Death-associated protein kinase 2 (DAPK2) Granulocytes migration with activation and differentiation [52] 2.36 (0.031)
Genes with functional overlap in Ob (osteoblast), Os (osteocyte) and Oc (osteoclast)
https://doi.org/10.1371/journal.pone.0197459.t001
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genetic footprint of response to pro-inflammatory stimulus in BM of SAO+ horses. Five of the
differentially expressed genes associated with the developing skeleton include DLX3,[59] Sp7
transcription factor (SP7),[40, 41] collagen type XXIV, alpha 1 (COL24A1),[37] collagen type
XI, alpha 2 (COLXIA2),[47] and chondroadherin (CHAD). [48] Increased transcription of
bone formation markers included integrin binding sialoprotein (BSP),[60, 61] osteocalcin
(OC),[62] and sphingomyelin phosphodiesterase 3 (SMPD3).[45, 46]
Tracheobronchial lymph node differential gene expression
Three out of 36 differentially expressed genes in the tLNs from SAO+ horses were included for
their functional relevance to the silicosis induced inflammatory process (Table 2). Six of the 36
genes were uncharacterized proteins. The other 27 genes were broadly associated with immune
functions and demonstrated a nonspecific pattern of differential expression (S3 Table).
Gene ontology (GO) enrichment analysis of bone marrow and
tracheobronchial lymph node transcriptomes
GO analysis probed the entire transcriptome of SAO+ and unaffected tissues against the struc-
tured dataset of biological functions to capture the significant differences in gene signaling and
interactions relative to biological processes. The data is presented in raw p-value for the Kol-
mogorov-Smirnov test for the over-represented GO terms (S4 and S5 Tables). (Raw p-values
are reported because there is no multiple testing correction method for hierarchically arranged
GO terms). Differences in biological functions were identified in BM and tLN tissues. The
order (P-value) revealed the statistical significance in the enriched biological function (S4 and
S5 Tables). In BM transcriptome, 326 enriched biologic functions associated with SAO had P
values<0.05 (S4 Table). The smallest p-value associated with enriched biological function was
osteoblast differentiation (p = 8.20E-05) with other top functions related to skeletal and vascu-
lar systems development (Fig 1 and S4 Table). In the affected tLN, 448 enriched biological
functions (P value <0.05) were broadly divided into immunological activation and few indica-
tors of infection (S5 Table, S4 Fig).
Panther analysis: PANTHER enrichment test
Increased signaling through the integrin (P00034, p = 5.91E-03), PDGF (P00047, p = 3.44E-
02) and cadherin (P00012, p = 6.58E-03) pathways were found in the SAO+ BM samples com-
pared to unaffected samples. Down-regulation of T cell activation (P00053, p = 1.51E-03),
increased coagulation (P00011, p = 7.87E-03), and decreased signaling through PDGF
(P00047, p = 7.92E-03) were over-represented pathways in affected tLN samples.
Table 2. Differentially expressed genes in tLN and base 2 logarithmic fold change with false discovery adjusted p-value. The selected three of the 36 differentially
expressed genes are listed for their relevance to SAO.
Gene (Names and symbol) Function Log2FC,
(PFDR)
Pentraxin 3 (PTX3) Macrophages, dendritic cells and stromal cells soluble pattern recognition receptor (response to insults like
silicates, infection and trauma);[53] identified as a promoter in TNF-α and IL-1β production through binding
NF-κB elements in vitro [54]
3.9 (0.029)
Equus caballus Fc fragment of IgA
receptor (FCAR)
Mediates immunological response in myeloid cells including alveolar macrophages that interact with IgA
engaged with its antigen [55]
2.20 (0.030)
Dentin matrix acidic phosphoprotein
1 (DMP1)
Tumor suppressor gene from calmodulin kinase family with broad function in cell signaling;[52] extracellular
matrix protein important for biomineralization;[56, 57] expressed in cancer with predilection for bone
metastases (eg. human lung cancer)[58]
3.01 (0.032)
https://doi.org/10.1371/journal.pone.0197459.t002
Transcriptome profile in equine osteoporotic condition associated with pulmonary silicosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0197459 June 1, 2018 8 / 20
Transcriptome profile in equine osteoporotic condition associated with pulmonary silicosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0197459 June 1, 2018 9 / 20
Morphological link to transcriptome patterns informed through DGE and
GO
BM and tLN sampled from the same site as tissues harvested for RNA were evaluated micro-
scopically to assess the biological relevance of the transcriptome data.
Bone marrow. Bone formation, resorption, and total perimeters were quantified in SAO+
and unaffected BM samples. Mean (± SD) ratio of bone forming surface to total bone surface
perimeter was greater (p<0.001) in SAO+ horses (0.31 ± 0.14) than unaffected horses
(0.05 ± 0.04). Osteoblast hypertrophy, captured as apical to basilar height, was significantly
greater (p = 0.002) in SAO+ horses (11.6 ± 2.2 μm) than unaffected horses (5.4 ± 3.8 μm).
Mean ratio of bone resorption surface to total bone surface perimeter was greater (p = 0.016)
in SAO+ horses (0.15 ± 0.12) than unaffected horses (0.03 ± 0.04). However, few osteoclasts
were present in sections (ranging from 0 to 6 per image area) compared to the other cell popu-
lations and numbers per total bone perimeter were not statistically different (p = 0.401)
between affected and unaffected horses. However, osteoclasts were subjectively more ubiqui-
tous in SAO+ horses with greater cell volume and nuclei numbers (Fig 2). Cartilaginous tissue
was not identified in the rib sections.
Tracheobronchial lymph nodes. The lymphoid follicles in SAO+ horses were atrophied
compared to the well-defined follicular architecture present in unaffected tLN samples (Fig 3).
Mild to moderate granulomatous inflammation and fibrosis obscured large regions of the tLN
medullary cords and cortex in the SAO+ group (Fig 3). Variable numbers of thin, refractile
Fig 1. The selected, significantly over-represented biological processes in SAO+ BM sample (based on raw p value<0.05). The
biological processes are listed in arbitrary categories associated with formation of bone (tan), cartilage (blue), embryonic skeleton
(green), vessels (pink), and immune system responses (gray). Bars represent negative Log 10 conversion of the p value to illustrate
the confidence in their over-representation in SAO+ BM. S4 Table includes the entire list of all the significant biological functions
for BM GO enrichment analysis.
https://doi.org/10.1371/journal.pone.0197459.g001
Fig 2. Representative photomicrographs of decalcified unaffected (A) and SAO+ (B) BM sections. Inter-trabecular BM stroma contained similarly mixed cell
populations. A thin layer of bone lining cells cover the trabecular bone surfaces in the control BM sample (A). Rows of osteoblasts (white arrows) line some of the bone
surfaces in SAO+ (B) and fewer surfaces in control (not shown) BM specimens. Rare osteoclasts (black arrows) are noted in the specimens but the osteoclasts and
associated resorption bays appear larger in SAO+ BM. [H&E stain; Scale bars 100 μm].
https://doi.org/10.1371/journal.pone.0197459.g002
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crystals (<2 μm long) were identified within regions of inflammation and fibrosis under polar-
ized light in tLNs only from affected horses. These crystals were non-pigmented and indistinct
under transmitted white light. Different refractile, brown pigmented crystals were observed in
10–30% of the sinusoidal macrophages of all tLNs. Necrosis, fibrosis, multinucleated macro-
phages, and inflammation were not associated with these crystals in tissues.
Fig 3. Photomicrographs of unaffected (A, C) and SAO+ tLNs (B, D). The affected tLN had regions of pallor in the cortex and medullary
cords (asterisks) subjacent to atrophied lymphoid follicles (“F”, B). Abundant mature and smudged collagen deposits (fibrosis) co-localized
with numerous macrophages, giant cells (arrow, D) and refractile, sharp crystalline particles (inset—high magnification of macrophage under
polarized light, D). Granular, pigmented crystals (black arrows and inset, A, C) consistent with incidental anthracosilicosis were noted in the
macrophages of both unaffected and affected tLNs (not shown in B, D) without inflammation, necrosis and fibrosis characteristic of reaction to
cytotoxic silicate crystals. Infectious organisms were not found in any lymph nodes. (c–lymph node capsule) [H&E stain; Scale bars: (A,B)
500μm; (C,D) 50μm].
https://doi.org/10.1371/journal.pone.0197459.g003
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Metatranscriptomic analysis
To determine if the presence of infectious agents was associated with the differential transcrip-
tome data from SAO+ and unaffected horses, metatranscriptomic analysis was conducted. In
all samples, reads assigned to Equus caballus comprised greater than 99.8% of all reads or read
pairs. The most abundant, non-equine species present in affected and control BM and tLN tis-
sues included Choristoneura occidentalis granulovirus (an arthropod virus, <0.09% of reads)
and Alteromonas mediterranea (a marine bacterium, <0.02% of reads). One SAO+ BM sample
had Mycobacterium tuberculosis as the second most abundant species (0.00017% of reads)
without microscopic evidence of granulomatous lesions.
Viral discovery
Metagenomic analysis was conducted on selected tissues from 3 SAO+ horses to determine if
viral genetic material could be detected. No viral RNA, despite the findings of granulovirus in
the metatranscriptomic analysis, was identified in pooled tissues (BM, tLN, blood, and lung).
Discussion
The cardinal lesions of SAO in tLN and bone marrow-rich skeletal sites were present in all
affected horses, supporting circumstantial evidence for their interconnected role in the pa-
thobiology of SAO.[1] The molecular signature within the microenvironment of affected pul-
monary and skeletal tissues was explored to enhance the understanding of SAO disease
pathogenesis. RNA-seq was used in the investigation of BM and tLN transcriptomes. To com-
pare the pattern of molecular signatures with the biological processes within BM and tLN tis-
sues, transcriptome results were assessed in light of the histologic features in the sites used for
molecular analysis. Several transcripts associated with bone formation (e.g., increased osteo-
blast-associated activity) and a lesser number for bone resorption were overrepresented in
SAO+ BM transcriptome relative to unaffected animals. DGE and GO enrichment analyses
demonstrated pro-inflammatory activity in SAO+ tLNs, but inherent tissue heterogeneity may
have diluted a more distinct transcriptome pattern. There was no evidence of infectious co-fac-
tors in SAO etiology. This study provides a novel viewpoint of a dominant molecular signature
of bone formation (increased osteoblastic activity) in a condition that has been morphologi-
cally defined by osteoclastic hyperactivity and clinically significant osteoporosis.[1] This data
introduced an unexpected conundrum.
Although unexpected, the paucity of transcripts associated with osteoclast differentiation in
SAO+ BM tissue suggests a number of pathogenic possibilities. Lack of anticipated transcrip-
tome pattern associated with increased signaling through pro-osteoclastogenic RANK may
reflect the low frequency of these transcripts within the complex cellular milieu of BM. Alter-
natively, the lack of evidence for a dominant osteoclastogenic signal may reflect the brief tem-
poral nature of such a signal. Regardless, within lesions characterized by abundant bone
removal, histologic evidence of overt osteoblastic activity is concurrently present. By design,
tissue RNA samples were obtained from grossly normal bone, anatomically distant from osteo-
porotic lesions.
DGE and GO enrichment analyses of the SAO+ BM transcriptome revealed predilection for
skeletal formation transcription. This finding was supported by morphologically increased
osteoblast activity in affected BM samples compared to quiescent bone surfaces of unaffected
tissues. Osterix (Sp7) is one of the differentially increased transcripts indicative of enhanced
osteoblast differentiation.[41] Expression of osteoblast activity markers downstream of Sp7
like IBSP, BGLAP and COL24A1 provided further transcriptional evidence of increased osteo-
blast differentiation in SAO+ BM.[43, 63, 64]
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Marked osteoblastic activity coupled with hyperactive osteoclasts is characteristic of SAO
lesions and other bone diseases like fibrous osteodystrophy. However, overrepresented activa-
tion of osteoblasts away from regions of intense osteolysis was not anticipated. Activation of
osteoblasts as a systemic reparative or compensatory mechanism despite minimal osteoclastic
activity within tested sample is a potential explanation. The results could be considered in the
context of increased mechanical loading distributed along weakened bone and increased dif-
ferentiation of BM stromal cells toward osteo-chondral lineage.[65] The induction of osteo-
blast differentiation by pro-inflammatory cytokines like Il-1β was also a new consideration.
[66] Trabecular osteocytes interact with BM stroma and may add to the pool of differentially
expressed genes like DLX3 and CDH15 shown to have a higher transcription level than osteo-
blasts in one study.[32]
Mechanisms involved in fetal bone formation are rekindled during endochondral ossifica-
tion in skeletal fracture repair and potentially activated in SAO+ BM. Increased transcripts in
our data are downstream of the master regulators of skeletal formation like bone morphoge-
netic protein (BMP) (reviewed by V.S. Salazar) [67] and runt related transcription factor 2
(Runx2) [68], (reviewed by T. Komori).[69] Transcriptional pattern of osteo-chondroprogeni-
tor cell differentiation is reflected in the DGE signature and enriched biological functions asso-
ciated with chondrocyte development and endochondral ossification despite histological
absence of cartilage in BM samples. For example, genes such as COLXIA2, SMPD3, TRPV4,
CHAD, and ANO5 are associated with cartilage tissue functions [45, 47] although cartilage and
endochondral ossification have not been reported in SAO osteolytic lesions. Skeletal tissue-ste-
reotypic genetic regulations of repair and embryonic pathways of the skeletal formation likely
overlap regardless of the mechanism of injury. The roles for the genes associated with endo-
chondral ossification and skeletal morphogenesis might be expanded as transcription patterns
within SAO bone lesions and appendicular skeletal sites rarely affected by osteoporosis are elu-
cidated in the future.
Increased osteoclast differentiation and activity in SAO+ BM was speculatively linked to the
increased transcription of SLC9A2, DLX3, TRPV4 and OMD.[27, 30, 36] The latter gene is up
regulated in an osteoblast response to osteoclastic activity.[28] Results from GO analysis did
not demonstrate biological functions associated with osteoclasts. The sensitivity of the tran-
scriptome analysis might not be sufficient to detect differential expression of osteoclasts out-
numbered in BM samples by other cell populations. Alternatively, osteoclast transcriptome
may be sample-dependent and thus indicative of multifocal rather than generalized nature of
the pro-osteoclastic differentiation and osteolysis in SAO.
Our results suggest a multifocal rather than systemic activation of an osteolytic trigger in
SAO. The multifocal distribution of osteolysis has been noted in post mortem examination
and on nuclear scintigraphic examination of SAO+ horses, but the potential significance has
not been realized.[1, 3] The putative differential transcriptome expression pattern may only be
captured within osteolytic lesions and would be sample site dependent. Additionally, the histo-
genic nature of the cytologically atypical, multinucleated, osteolytic cells in SAO may need to
be defined beyond microscopic phenotype together with the histogenesis of their precursors.
Nevertheless, our results bring attention to osteoblasts and their multidimensional role in
bone tissue formation, regulation of their microenvironment, and implication in pathogenesis
of bone fragility diseases.
The role of the only down-regulated transcript, HSD17B6, in SAO+ BM is unclear because
function of the equine isoenzyme is not defined in the literature. HSD17B6might have an
important role in bone as some isoenzymes catalyze the interconversion of estrone (E1) to
“osteoprotective” estradiol E2).[51] In human and mice prostate tissues, HSD17B6 has been
identified as a mediator of the conversion of androgen substrates into inactive forms.[70]
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Depending on the substrate and the product of the hydroxysteroid dehydrogenase, depletion
of HSD17B6 in SAO+ horses could be a response to accelerated bone loss, or part of the disease
pathobiology resulting in excessive osteolysis.
Compared to GO and DGE analysis, PANTHER pathway evaluation of the BM transcrip-
tome did not explicitly demonstrate osteoblast-associated functions. Pathway analysis showed
increased signaling through the integrin and cadherin pathways broadly used by cells in the
BM tissue.
Both DGE and GO enrichment analyses showed evidence for nonspecific inflammation in
the tLNs of SAO+ horses. DGE analysis did not reveal a transcription pattern to explain the
association between the skeleton and lung conditions in SAO. The 30 functionally defined dif-
ferentially expressed genes within the SAO+ tLNs showed variably regulated transcripts
broadly related to immune system functions. Theoretically, connections between silicosis and
osteoporosis could be made with some transcripts. For example, an increase in DMP1 tran-
scription echoes BM tropism of an osteolytic trigger in SAO because it was up-regulated in
bone tropic metastatic lung cancers.[58] Physiologic expression of DMP1 in non-mineralized
tissues may indicate a wider purpose for extra-skeletal regulation of mineralization.[71] PTX3
up-regulation may have some connection with silicosis as a promoter in TNF-α and IL-1β pro-
duction through binding NF-κB elements, as demonstrated in vitro.[54] Increased production
of IL-1 and TNF-α has been implicated in the pathobiology of silicosis.[72, 73] Interestingly,
PTX3 is increased in cultured human bronchial epithelial cells exposed to cytotoxic silicates.
[74] Inherent cell population variability within affected and unaffected tLN tissues may have
distorted the signal pattern of the silicosis and diluted the significant differentially expressed
genes. Heterogeneity included regions where more than 40% of affected tLN had been replaced
by fibrosis, necrosis, and granulomatous inflammation in response to intralesional refractile
crystals (presumed cristobalite).
Modification of the tissue target, sample collection, and RNA preparation protocols, as well
as identification of SAO clinical markers would curtail some of the limitations for the prospec-
tive investigation of this condition. Because necropsy and histopathology remain the gold stan-
dard diagnostic tools to confirm SAO, only horses in terminal condition were recruited for
the study. Concerns over transportation of severely affected SAO+ horses with advanced os-
teoporosis resulted in challenging barriers for patient recruitment. Isolation of the specific cell
targets from BM and blood of live animals, such as osteoblasts or osteoclasts using laser dissec-
tion, and monocytes with a cell sorting technique may prove useful for future studies. The
implication of the results from the metatranscriptomic analysis in our study was unclear since
the low frequency transcripts of an arthropod virus and marine bacteria were present in all the
samples. Misclassification of the non-equine transcripts was considered as a possibility. The
finding of low frequency transcripts of Mycobacterium tuberculosis in one SAO+ BM sample
was not supported by clinical and pathological examination. Elimination of the poly A RNA
selection step would potentially resolve limitations of the metatranscriptomic analysis in
including infectious agents that do not transcribe their genetic material in this RNA form.
In conclusion, the data revealed an SAO associated transcriptome profile in BM tissue
skewed toward skeletal formation which is also supported by microscopic findings (at bone
sites distinct from lesions of osteolysis). The hypothesized molecular signal of a pathogenic
link connecting the pulmonary and skeletal lesions was not elucidated by our results, and
increased transcripts associated with osteoclast differentiation and activation were relatively
fewer than osteoblast related transcripts. A clear transcriptome pattern was not identified
between affected and unaffected animals due to the cellular heterogeneity in the tLN samples.
Specific cell targets from the BM and tLN tissues would address the potential dilution of the
disease-specific transcriptome pattern. Transcriptome profile of osteoclasts, osteoclast
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precursors or macrophages from osteolytic SAO lesions may provide better understanding of
osteoclast dysregulation. The effect of ongoing pulmonary inflammation and silicosis on oste-
oblasts and regulation of bone formation warrants investigation in light of our findings. This is
the first study that uses RNA-seq technology in investigation of disease mechanism in the
equine co-morbid condition though RNA-seq has been used in research of other equine dis-
eases.[75–79] SAO may provide an opportunity for a unique understanding of mechanisms in
an environmentally induced condition with pulmonary/tLN and skeletal comorbidity.
Supporting information
S1 Fig. BM and tLN MDS plot. The sequenced samples transcript patterns cluster based on
tissue in this MDS plot that simultaneously evaluated BM and tLN transcriptomes together.
(TIF)
S2 Fig. BM MDS plot. BM MDS plot demonstrates clustering of cases (red) based on bone
phenotype. The group with mild osteoporosis (encircled in black) co-localized with control
cases.
(TIF)
S3 Fig. tLN MDS plot. tLN MDS plot demonstrates clustering of control cases and wider dis-
persal of the cases transcriptome profiles.
(TIF)
S4 Fig. tLN GO enrichment chart. The most enriched biological processes related infectious
agents like virus and bacterial elements in the SAO+ tLN with raw p-value <0.05 are included
in the bar chart. Bars represent -Log 10 converted p values. S5 Table includes the entire list of
all the significant biological functions for tLN GO enrichment analysis.
(TIF)
S5 Fig. Sex and age do not have effect on distribution of BM transcriptome in the MDS
plot.
(TIF)
S6 Fig. Sex and age do not have effect on distribution of tLN transcriptome in the MDS
plot.
(TIF)
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(BM RIN) and tLN (LN RIN) for SAO+ and Control horses.
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